Author

T. Zuo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Pharmacology & Toxicology· 2 Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 6 Research Focus:cell type annotation· 5 Assay:proteomics· 5 Research Focus:differential expression· 4 Research Focus:gene regulatory network inference· 3 Research Focus:host-pathogen & immune response· 3 Assay:bulk RNA-seq· 2

Frequent Co-Authors

Y. Li· 3 shared F. Xu· 2 shared H. Feng· 2 shared J. Li· 2 shared K. Li· 2 shared L. Chang· 2 shared L. Jiang· 2 shared L. Li· 2 shared

Activity by Year

2019-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

Y. Li

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Ancestral SARS-CoV-2 immune imprinting persists on RBD but not NTD after sequential Omicron infections

Z. Wang, L. Li, R. Du, X. Chen, Y. Sun, R. Qin, Y. Li, H. Feng, L. Hu, X. Chen, M. Lu, L. Jiang, T. Zuo

The paper examines how sequential Omicron infections affect ancestral SARS-CoV-2 immune imprinting, finding that it persists on the RBD but not the NTD.

iScience · Jan 1, 2025Peer-reviewedImmunology

The phosphoproteome is a first responder in tiered cellular adaptation to chemical stress followed by proteomics and transcriptomics alteration

P. Chen, Y. Li, F. Xu, Z. Zhang, T. Zuo, J. Guo, K. Li, S. Liu, S. Li, J. Yin, L. Chang, P. Kukic, M. Liddell, L. Tulum, P. Carmichael, , P. Xu

This study compares transcriptomics, proteomics, and phosphoproteomics responses in HepG2 and AC16 cells to chemical exposure, finding phosphoproteomics changes occur earlier and at lower concentrations than transcriptomics.

Chemosphere · Dec 1, 2023Peer-reviewedPharmacology & Toxicology

Breakthrough infection elicits hypermutated IGHV3-53/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including BQ and XBB lineages

L. Li, X. Chen, Z. Wang, Y. Li, C. Wang, L. Jiang, T. Zuo

This study identifies hypermutated IGHV3-53/3-66 antibodies from breakthrough infections that broadly neutralize SARS-CoV-2 variants including BQ and XBB.

bioRxiv · Jul 18, 2023 · PreprintImmunology

Treg cells drive MYCN-mediated immunosuppression and tumor aggressiveness in high-risk neuroblastoma

X. Qin, A. K. Lam, X. Zhang, S. Sengupta, B. J. Iorgulescu, T. Zuo, A. E. Floru, G. K. Meara, k. Lloyd, L. A. Kwok, K. S. Smith, T. R. Nagaraju, R. Meijers, C. Ceol, C.-T. Liu, , H. Feng

This study shows Treg cells drive MYCN-mediated immunosuppression and tumor aggressiveness in high-risk neuroblastoma using human and zebrafish models.

bioRxiv · Oct 3, 2022 · PreprintCancer Biology

Using NAMs to characterize chemical bioactivity at the transcriptomic, proteomic and phosphoproteomic levels

Y. Li, Z. zhang, S. Jiang, F. Xu, L. Tulum, K. Li, S. Liu, S. Li, L. Chang, M. Liddell, F. Tu, X. Gu, P. L. Carmichael, A. White, S. Peng, , P. Xu

This paper integrates multi-omic data to characterize chemical bioactivity at transcriptomic, proteomic, and phosphoproteomic levels, showing how early phosphoproteomic changes drive downstream effects.

bioRxiv · May 18, 2022 · PreprintPharmacology & Toxicology

Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike

P. Tong, A. Gautam, I. Windsor, M. Travers, Y. Chen, N. Garcia, N. Whiteman, L. McKay, F. J. N. Lelis, S. Habibi, Y. Cai, L. J. Rennick, W. P. Duprex, K. McCarthy, C. L. Lavine, , D. R. Wesemann

The paper maps memory B cell receptors against SARS-CoV-2 spike variants, identifying 7 mAb competition groups and their epitopic regions, and shows their cross-reactivity and neutralization properties.

bioRxiv · Mar 10, 2021Immunology

BR-bodies provide selectively permeable condensates that stimulate mRNA decay and prevent release of decay intermediates

N. Al-Husini, D. T. Tomares, Z. Pfaffenberger, N. S. Muthunayake, M. A. Samad, T. Zuo, O. Bitar, J. R. Aretakis, M. H. M. Bharmal, A. Gega, J. S. Biteen, W. S. Childers, J. M. Schrader

The paper identifies RNA substrates of BR-bodies and shows they stimulate mRNA decay while preventing toxic intermediates.

bioRxiv · Jul 5, 2019Biochemistry